Ces radiol. 2020, 74(3):202-210 | DOI: 10.55095/CesRadiol2020/031

CT findings of the most common adrenal tumours - pictorial essayPicture essay

Filip Čtvrtlík1, Jakub Čivrný1, Paulína Szász1, František Odstrčil2, Zbyněk Tudos1
1 Radiologická klinika LF UP a FN, Olomouc
2 Ústav radiologických metod, Fakulta zdravotnických věd LF UP a FN, Olomouc

The authors provide a summary of common adrenal gland tumours encountered in radiology, with an emphasis on CT findings. The first to be mentioned is adrenal adenoma, which is the most common pathological finding of adrenals and which is often incidental. Its lipid-rich variant has a typical imaging pattern. Other benign adrenal gland tumours include myelolipoma, which also has typical imaging characteristics, and pheochromocytoma, which may show certain warning CT features, which should draw our attention towards this entity, which often manifests with hypertension. Adrenocortical carcinoma, which has a high case fatality rate and tends to be large, is a very aggressive adrenal gland tumour. Adrenal gland metastases mark the dissemination of carcinoma, which usually has epithelial origin. Unfortunately, metastases have variable characteristics, including their size. The ability to recognise these nosologic entities is important for further management as some of them do not require treatment or follow-up, while, on the contrary, some demand an active therapeutic approach.

Keywords: adenoma, myelolipoma, pheochromocytoma, adrenocortical carcinoma, metastases, computed tomography
Grants and funding:

Podpořeno z programového projektu Ministerstva zdravotnictví ČR reg. č. 17-31847A a vnitřním grantem Univerzity Palackého reg. č. IGA_LF_2020_012. 1c

Accepted: August 1, 2020; Published: September 1, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Čtvrtlík F, Čivrný J, Szász P, Odstrčil F, Tudos Z. CT findings of the most common adrenal tumours - pictorial essay. Ces radiol. 2020;74(3):202-210. doi: 10.55095/CesRadiol2020/031.
Download citation

References

  1. Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. European Journal of Endocrinology 2016; 175(2): G1-G34. Go to original source... Go to PubMed...
  2. Grumbach MM, Biller BMK, Braunstein GD, et al. Management of the clinically inapparent adrenal mass (incidentaloma). Ann Intern Med 2003; 138(5): 424-429. Go to original source... Go to PubMed...
  3. Korobkin M, Brodeur FJ, Yutzy GG, et al. Differentiation of adrenal adenomas from nonadenomas using CT attenuation values. AJR Am J Roentgenol 1996; 166(3): 531-536. Go to original source... Go to PubMed...
  4. Boland GW, Lee MJ, Gazelle GS, Halpern EF, McNicholas MM, Mueller PR. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR Am J Roentgenol 1998; 171(1): 201-204. Go to original source... Go to PubMed...
  5. Dunnick NR, Korobkin M. Imaging of Adrenal Incidentalomas: Current Status. American Journal of Roentgenology 2002; 179(3): 559-568. Go to original source... Go to PubMed...
  6. Hamrahian AH, Ioachimescu AG, Remer EM, et al. Clinical utility of noncontrast computed tomography attenuation value (hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland Clinic experience. J Clin Endocrinol Metab 2005; 90(2): 871-877. Go to original source... Go to PubMed...
  7. Lockhart ME, Smith JK, Kenney PJ. Imaging of adrenal masses. Eur J Radiol 2002; 41(2): 95-112. Go to original source... Go to PubMed...
  8. Mayo-Smith WW, Boland GW, Noto RB, Lee MJ. State-of-the-art adrenal imaging. Radiographics 2001; 21(4): 995-1012. Go to original source... Go to PubMed...
  9. Udelsman R, Fishman EK. Radiology of the adrenal. Endocrinol Metab Clin North Am 2000; 29(1): 27-42, viii. Go to original source... Go to PubMed...
  10. Bae KT, Fuangtharnthip P, Prasad SR, Joe BN, Heiken JP. Adrenal Masses: CT Characterization with Histogram Analysis Method. Radiology 2003; 228(3): 735-742. Go to original source... Go to PubMed...
  11. Tüdös Z, Kučera P, Szász P, et al. Influence of slice thickness on result of CT histogram analysis in indeterminate adrenal masses. Abdom Radiol 2019; 44(4): 1461-1469. Go to original source... Go to PubMed...
  12. Reimer P, Parizel PM, Stichnoth F-A. Clinical MR imaging: A practical approach (Second, completely revised and updated edition). Berlin-Heidelberg-New York: Springer-Verlag 2006. Go to original source...
  13. Savci G, Yazici Z, Sahin N, Akgöz S, Tuncel E. Value of chemical shift subtraction MRI in characterization of adrenal masses. AJR Am J Roentgenol 2006; 186(1): 130-135. Go to original source... Go to PubMed...
  14. Boland GWL, Dwamena BA, Jagtiani Sangwaiya M, et al. Characterization of adrenal masses by using FDG PET: a systematic review and meta-analysis of diagnostic test performance. Radiology 2011; 259(1): 117-126. Go to original source... Go to PubMed...
  15. Čtvrtlík F, Kučera P, Sedláčková Z, et al. Přítomnost kalcifikací v nádorech nadledvin - jsou skutečně typické pro adrenokortikální karcinomy? Ces Radiol 2020; 74(1): 28-32. Go to original source...
  16. Dahia PLM. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nat Rev Cancer 2014; 14(2): 108-119. Go to original source... Go to PubMed...
  17. Lenders JWM, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet 2005; 366(9486): 665-675. Go to original source... Go to PubMed...
  18. Lenders JWM, Duh Q-Y, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99(6): 1915-1942. Go to original source... Go to PubMed...
  19. Crona J, Taïeb D, Pacak K. New Perspectives on Pheochromocytoma and Paraganglioma: Towards a Molecular Classification. Endocr Rev 2017; 38(6): 489-515. Go to original source... Go to PubMed...
  20. Gruber LM, Hartman RP, Thompson GB, et al. Pheochromocytoma Characteristics and Behavior Differ Depending on Method of Discovery. J Clin Endocrinol Metab 2019; 104(5): 1386-1393. Go to original source... Go to PubMed...
  21. Falhammar H, Kjellman M, Calissendorff J. Treatment and outcomes in pheochromocytomas and paragangliomas: a study of 110 cases from a single center. Endocrine 2018; 62(3): 566-575. Go to original source... Go to PubMed...
  22. Čtvrtlík F, Heřman M, Študent V, Tichá V, Minařík J. Differential diagnosis of incidentally detected adrenal masses revealed on routine abdominal CT. Eur J Radiol 2009; 69(2): 243-252. Go to original source... Go to PubMed...
  23. Korobkin M, Brodeur FJ, Francis IR, Quint LE, Dunnick NR, Londy F. CT time-attenuation washout curves of adrenal adenomas and nonadenomas. Am J Roentgenol 1998; 170(3): 747-752. Go to original source... Go to PubMed...
  24. Caoili EM, Korobkin M, Francis IR, Cohan RH, Dunnick NR. Delayed enhanced CT of lipid-poor adrenal adenomas. Am J Roentgenol 2000; 175(5): 1411-1415. Go to original source... Go to PubMed...
  25. Szolar DH, Korobkin M, Reittner P, et al. Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT. Radiology 2005; 234(2): 479-485. Go to original source... Go to PubMed...
  26. Kumagae Y, Fukukura Y, Takumi K, et al. Distinguishing adrenal adenomas from non-adenomas on dynamic enhanced CT: a comparison of 5 and 10 min delays after intravenous contrast medium injection. Clin Radiol 2013; 68(7): 696-703. Go to original source... Go to PubMed...
  27. Patel J, Davenport MS, Cohan RH, Caoili EM. Can established CT attenuation and washout criteria for adrenal adenoma accurately exclude pheochromocytoma? Am J Roentgenol 2013; 201(1): 122-127. Go to original source... Go to PubMed...
  28. Schieda N, Alrashed A, Flood TA, Samji K, Shabana W, McInnes MDF. Comparison of Quantitative MRI and CT Washout Analysis for Differentiation of Adrenal Pheochromocytoma From Adrenal Adenoma. Am J Roentgenol 2016; 206(6): 1141-1148. Go to original source... Go to PubMed...
  29. Bessell-Browne R, O'Malley ME. CT of pheochromocytoma and paraganglioma: risk of adverse events with i.v. administration of nonionic contrast material. Am J Roentgenol 2007; 188(4): 970-974. Go to original source... Go to PubMed...
  30. Ctvrtlik F, Tudos Z, Szasz P, et al. Characteristic CT features of pheochromocytomas - probability model calculation tool based on a multicentric study. Biomedical Papers 2019; 163(3): 212-219. Go to original source... Go to PubMed...
  31. Shellock FG, Kanal E. Safety of magnetic resonance imaging contrast agents. J Magn Reson Imaging 1999; 10(3): 477-484. Go to original source...
  32. Taïeb D, Timmers HJ, Hindié E, et al. EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2012; 39(12): 1977-1995. Go to original source... Go to PubMed...
  33. Taïeb D, Hicks RJ, Hindié E, et al. European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2019; 46(10): 2112-2137. Go to original source... Go to PubMed...
  34. Veverková L, Čtvrtlík F, Buriánková E, et al. Breast cancer and pheochromocytoma - a case report about rare synchronous tumor occurence. Ces Radiol 2018; 72(1): 42-47. Go to original source...
  35. Vyakaranam AR, Crona J, Norlén O, Hellman P, Sundin A. 11C-hydroxy-ephedrine-PET/CT in the Diagnosis of Pheochromocytoma and Paraganglioma. Cancers (Basel) 2019; 11(6)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627429/. Accessed June 11, 2020. Go to original source... Go to PubMed...
  36. Ayala-Ramirez M, Jasim S, Feng L, et al. Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol 2013; 169(6): 891-899. Go to original source... Go to PubMed...
  37. Wang S, Chen S-S, Gao W-C, et al. Prognostic Factors of Adrenocortical Carcinoma: An Analysis of the Surveillance Epidemiology and End Results (SEER) Database. Asian Pac J Cancer Prev 2017; 18(10): 2817-2824.
  38. Else T, Kim AC, Sabolch A, et al. Adrenocortical Carcinoma. Endocr Rev 2014; 35(2): 282-326. Go to original source... Go to PubMed...
  39. Fassnacht M, Dekkers OM, Else T, et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 2018; 179(4): G1-G46. Go to original source... Go to PubMed...
  40. Ganeshan D, Bhosale P, Kundra V. Current update on cytogenetics, taxonomy, diagnosis, and management of adrenocortical carcinoma: what radiologists should know. Am J Roentgenol 2012; 199(6): 1283-1293. Go to original source... Go to PubMed...
  41. Libè R, Fratticci A, Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer 2007; 14(1): 13-28. Go to original source... Go to PubMed...
  42. Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 2000; 85(2): 637-644. Go to original source... Go to PubMed...
  43. Zhang HM, Perrier ND, Grubbs EG, et al. CT features and quantification of the characteristics of adrenocortical carcinomas on unenhanced and contrast-enhanced studies. Clin Radiol 2012; 67(1): 38-46. Go to original source... Go to PubMed...
  44. Ahn SH, Kim JH, Baek SH, et al. Characteristics of Adrenal Incidentalomas in a Large, Prospective Computed Tomography-Based Multicenter Study: The COAR Study in Korea. Yonsei Med J 2018; 59(4): 501-510. Go to original source... Go to PubMed...
  45. Čtvrtlík F, Kučera P, Szász P, et al. Přínos měření velikosti náhodně zachycené expanze nadledviny v diferenciální diagnostice incidentalomů. Ces Radiol 2019; 73(4): 235-239. Go to original source...
  46. Ozsari L, Kutahyalioglu M, Elsayes KM, et al. Preexisting adrenal masses in patients with adrenocortical carcinoma: clinical and radiological factors contributing to delayed diagnosis. Endocrine 2016; 51(2): 351-359. Go to original source... Go to PubMed...
  47. Kostiainen I, Hakaste L, Kejo P, et al. Adrenocortical carcinoma: presentation and outcome of a contemporary patient series. Endocrine 2019; 65(1): 166-174. Go to original source... Go to PubMed...
  48. Petersenn S, Richter P-A, Broemel T, et al. Computed tomography criteria for discrimination of adrenal adenomas and adrenocortical carcinomas: analysis of the German ACC registry. Eur J Endocrinol 2015; 172(4): 415-422. Go to original source... Go to PubMed...
  49. Blake MA, Cronin CG, Boland GW. Adrenal imaging. Am J Roentgenol 2010; 194(6): 1450-1460. Go to original source... Go to PubMed...

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.